retatrutide news recency 3 GLP-3 (Reta) 10mg Retatrutide Phase 3 Results: TRIUMPH-1

Patients were categorized into four treatment groups: (i) both SGLT2-I and GLP-1RA, (ii) SGLT2-I only, (iii) GLP-1RA only, and (iv) neither medication

Receptor Occupancy Across the Dosing Cycle Receptor-occupancy modeling from Eli Lilly's Phase I data shows that at steady-state 15 mg dosing, trough plasma concentrations maintain greater than 80% GLP-1R occupancy and greater than 70% GIPR occupancy in beta-cells [28]

In the past six months, the agency stated it has sent thousands of letters to pharmaceutical and telehealth companies directing them to remove misleading advertisements, more than had been sent over the entire preceding decade

Find out in a free phone consultation